» Articles » PMID: 36970215

Progress in the Studies on the Molecular Mechanisms Associated with Multidrug Resistance in Cancers

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2023 Mar 27
PMID 36970215
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy is one of the important methods to treat cancer, and the emergence of multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy. Almost all anti-tumor drugs develop drug resistance over a period of time of application in cancer patients, reducing their effects on killing cancer cells. Chemoresistance can lead to a rapid recurrence of cancers and ultimately patient death. MDR may be induced by multiple mechanisms, which are associated with a complex process of multiple genes, factors, pathways, and multiple steps, and today the MDR-associated mechanisms are largely unknown. In this paper, from the aspects of protein-protein interactions, alternative splicing (AS) in pre-mRNA, non-coding RNA (ncRNA) mediation, genome mutations, variance in cell functions, and influence from the tumor microenvironment, we summarize the molecular mechanisms associated with MDR in cancers. In the end, prospects for the exploration of antitumor drugs that can reverse MDR are briefly discussed from the angle of drug systems with improved targeting properties, biocompatibility, availability, and other advantages.

Citing Articles

AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer.

Fu Z, Wu T, Gao C, Wang L, Zhang Y, Shi C Acta Pharm Sin B. 2025; 14(12):5305-5320.

PMID: 39807317 PMC: 11725136. DOI: 10.1016/j.apsb.2024.08.031.


Role of ABCC5 in cancer drug resistance and its potential as a therapeutic target.

Pan Y, Wu M, Cai H Front Cell Dev Biol. 2024; 12:1446418.

PMID: 39563862 PMC: 11573773. DOI: 10.3389/fcell.2024.1446418.


IGFBP7 regulates cell proliferation and migration through JAK/STAT pathway in gastric cancer and is regulated by DNA and RNA methylation.

Mo W, Deng L, Cheng Y, Ge S, Wang J J Cell Mol Med. 2024; 28(19):e70080.

PMID: 39351597 PMC: 11443158. DOI: 10.1111/jcmm.70080.


Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition.

Yoo H, Kim Y, Kim J, Cho H, Kim K Molecules. 2024; 29(17).

PMID: 39274842 PMC: 11396748. DOI: 10.3390/molecules29173994.


Neighboring Effect-Initiated Supramolecular Nanocomplex with Sequential Infiltration as Irreversible Apoptosis Inducer for Synergetic Chemo-Immunotherapy.

Ye M, Hu J, Han L, Zhang H, Xue P, Kang Y Adv Sci (Weinh). 2024; 11(38):e2402809.

PMID: 39137339 PMC: 11481388. DOI: 10.1002/advs.202402809.


References
1.
Ma S, Kong D, Fu X, Liu L, Liu Y, Xue C . p53-Induced Autophagy Regulates Chemotherapy and Radiotherapy Resistance in Multidrug Resistance Cancer Cells. Dose Response. 2021; 19(4):15593258211048046. PMC: 8504250. DOI: 10.1177/15593258211048046. View

2.
Zhuo W, Hu L, Lv J, Wang H, Zhou H, Fan L . Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol. 2014; 74(2):217-27. PMC: 4386062. DOI: 10.1007/s00280-014-2494-9. View

3.
Jiang W, Chen L, Guo X, Cheng C, Luo Y, Wang J . Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy. Theranostics. 2022; 12(6):2987-3006. PMC: 8965496. DOI: 10.7150/thno.71693. View

4.
Chang F, Ling Y, Lai M . Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Anticancer Res. 2000; 20(1A):329-36. View

5.
Taylor N, Manolaridis I, Jackson S, Kowal J, Stahlberg H, Locher K . Structure of the human multidrug transporter ABCG2. Nature. 2017; 546(7659):504-509. DOI: 10.1038/nature22345. View